- Dupilumab is associated with improved signs, symptoms, and/or QoL in adolescent patients with moderate-to-severe atopic dermatitis (AD), according to post hoc analysis of the LIBERTY AD ADOL randomised controlled trial.
Why this matters
- This study demonstrated benefits of dupilumab using a comprehensive evaluation combining clinician- and patient-reported outcome measures.
- Dupilumab was associated with a higher rate of clinically meaningful improvements in AD signs, symptoms, and/or QoL compared with placebo:
- Q2W dosing: 80.5% vs 23.5% (P<.0001>
- Q4W: 63.1% vs 23.5% (P<.0001>
- Q2W: 74.2% vs 21.7% (P<.0001>
- Q4W: 55.1% vs 21.7% (P<.0001>
- 251 patients ages ≥12 to
- Funding: Sanofi; Regeneron Pharmaceuticals, Inc.
- Not prespecified outcomes.